The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myeloma
Dean Smith, BA(Hons), MBBS, MRCP, FRCPath, MD(Res), Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses the design of the ongoing single-arm Phase II MODIFY trial (NCT06762769) evaluating the combination of isatuximab, iberdomide, and dexamethasone in patients with high-risk smoldering multiple myeloma (SMM) with the aim of preventing progression to active myeloma. Dr Smith outlines the eligibility criteria and co-primary and secondary endpoints. He also explains that the observational COSMOS study is being used as a comparator and describes a patient-reported outcome measures (PROMs) program assessing quality of life and attitudes towards treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
